Hemex Health announces breakthrough measurement capability for clinicians monitoring sickle cell disease therapy – QNT Press Release

PORTLAND, Ore. and MUMBAI, India, May 08, 2022 (GLOBE NEWSWIRE) — Hemex Healtha Portland, Oregon-based health-tech startup, announced a significant enhancement to their Gazelle™ Hb Variant test, which allows for more precise measurements of Hb F, also known as fetal hemoglobin. The increased accuracy could be useful for monitoring hydroxyurea therapy in point-of-care settings.

The software upgrade comes just months after the company released an enhancement that allows its Hb Variant test to detect beta thalassemia disease and trait in addition to sickle cell disease (SCD) and trait.

“We are excited to make this announcement on World Thalassemia Day to help raise awareness for severe blood disorders,” said Patti…

Full story available on Benzinga.com

Source link

Recommended For You

About the Author: News Center